Temocapril, an angiotensin converting-enzyme (ACE) inhibitor, improves insulin resistance in type 2 diabetic mice by way of the bradykinin-nitric oxide system, according to a report in the September issue of Hypertension.
ACE inhibitor treatment results in an accumulation of kinins, the authors explain, which, in turn, results in an increase in nitric oxide. Both bradykinin and nitric oxide appear to enhance glucose uptake independently of insulin.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!